



SpectraScience Secures Distribution for WavSTAT® Cancer Diagnosis System in Italy

SAN DIEGO, June 9, 2008 (PR NEWSWIRE) – SpectraScience, Inc. (OTCBB:SCIE), a San Diego based medical device company, today announced that it has established a distribution partnership for the Italian market through Medimar Italia, a Milan-based firm specializing in medical device sales in the country.

Michel Vaudry, SpectraScience’s Director of International Sales commented that, “We are pleased to have added our second European distributor in the past two months. Medimar is a respected and well-established medical device distributor and its decision to add the WavSTAT Optical Biopsy System to their portfolio is a strong validation of our technology.”

Medimar’s President, Francesco Torelli, stated that, “SpectraScience’s WavSTAT has tremendous potential to impact the marketplace here in Italy. The importance of earlier and more effective screening for colon cancer cannot be stressed enough and we look forward to representing the product and working with SpectraScience to build and grow the Italian market presence.”

Vaudry added that “Mr. Torelli is a respected thought leader in the medical device market in Italy, so his support of the WavSTAT System will be instrumental in our acceptance into the major gastroenterology centers in the country.”

Key Benefits to the WavSTAT Optical Biopsy System

- Helps the physician discern between normal and pre-cancerous tissue in the GI tract
- Gives the physician additional information that allows for a more informed decision on leaving polyps on site if they are not pre-cancerous thereby minimizing risks and time
- Provides the opportunity for physicians to perform a physical biopsy at exactly the same site and time that the optical biopsy is performed
- Allows physicians to determine the margin, or border of the pre-cancerous tissue
- Aids physicians during colon cancer surgery to determine if all cancerous tissue has been removed
- Is complementary to NBI and Smart Pill and other recent evaluating technologies (e.g. Olympus, Pentax, Fujinon, Given)

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise

interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA[®] cervical imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.

Contact:

SpectraScience, Inc.
Jim Hitchin, Chief Executive Officer
(858) 847-0200 x201
www.spectrascience.com

Hayden Communications
Investor Relations
Todd Pitcher
(858)-518-1387